A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

(2013) J.A. French et al.   ACTA NEUROLOGICA SCANDINAVICA

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial

(2013) Victor Biton et al.   EPILEPSIA

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial

(2013) Patrick Kwan et al.   EPILEPSIA

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial

(2013) Philippe Ryvlin et al.   EPILEPSIA

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Patterns of treatment response in newly diagnosed epilepsy

(2012) M. J. Brodie et al.   NEUROLOGY

Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma

(2011) Wolfgang Löscher et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Estimation of the burden of active and life-time epilepsy: A meta-analytic approach

(2010) Anthony K. Ngugi et al.   EPILEPSIA

Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

(2010) J. A. French et al.   NEUROLOGY

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study

(2009) Christian Elger et al.   EPILEPSIA

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY